BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li JH, Joy SV, Haga SB, Orlando LA, Kraus WE, Ginsburg GS, Voora D. Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients. J Pers Med 2014;4:147-62. [PMID: 25563221 DOI: 10.3390/jpm4020147] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Bharath G, Vishnuprabu DP, Preethi L, Nagappan AS, Dhianeshwaran Isravanya RT, Bhaskar LV, Swaminathan N, Munirajan AK. SLCO1B1 and ABCB1 variants synergistically influence the atorvastatin treatment response in south Indian coronary artery disease patients. Pharmacogenomics 2022. [PMID: 35968761 DOI: 10.2217/pgs-2022-0044] [Reference Citation Analysis]
2 Melhem AL, Chourasia MK, Bigossi M, Maroteau C, Taylor A, Pola R, Dawed AY, Tornio A, Palmer CNA, Siddiqui MK. Common Statin Intolerance Variants in ABCB1 and LILRB5 Show Synergistic Effects on Statin Response: An Observational Study Using Electronic Health Records. Front Genet 2021;12:713181. [PMID: 34659336 DOI: 10.3389/fgene.2021.713181] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Jessurun NT, Drent M, Wijnen PA, Harmsze AM, van Puijenbroek EP, Bekers O, Bast A. Role of Drug-Gene Interactions and Pharmacogenetics in Simvastatin-Associated Pulmonary Toxicity. Drug Saf 2021;44:1179-91. [PMID: 34606062 DOI: 10.1007/s40264-021-01105-8] [Reference Citation Analysis]
4 Wang T, Sun L, Xu L, Zhao T, Feng J, Yu L, Wu J, Li H. Prevalence of dyslipidemia and gene polymorphisms of ABCB1 and SLCO1B1 in Han, Uygur, Kazak, Hui, Tatar, Kirgiz, and Sibe populations with coronary heart disease in Xinjiang, China. Lipids Health Dis 2021;20:116. [PMID: 34563206 DOI: 10.1186/s12944-021-01544-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Brunette CA, Vassy JL. The role of SLCO1B1 genotyping in lowering cardiovascular risk. Pharmacogenomics 2021;22:649-56. [PMID: 34196599 DOI: 10.2217/pgs-2021-0075] [Reference Citation Analysis]
6 Hicks JK, El Rouby N, Ong HH, Schildcrout JS, Ramsey LB, Shi Y, Anne Tang L, Aquilante CL, Beitelshees AL, Blake KV, Cimino JJ, Davis BH, Empey PE, Kao DP, Lemkin DL, Limdi NA, P Lipori G, Rosenman MB, Skaar TC, Teal E, Tuteja S, Wiley LK, Williams H, Winterstein AG, Van Driest SL, Cavallari LH, Peterson JF; IGNITE Pharmacogenetics Working Group. Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems. Clin Pharmacol Ther 2021;110:179-88. [PMID: 33428770 DOI: 10.1002/cpt.2161] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
7 Chan SL, Liew HZW, Nguyen F, Thumboo J, Chow WC, Sung C. Prescription patterns of outpatients and the potential of multiplexed pharmacogenomic testing. Br J Clin Pharmacol 2021;87:886-94. [PMID: 32559336 DOI: 10.1111/bcp.14439] [Reference Citation Analysis]
8 Christian C, Borden BA, Danahey K, Yeo KJ, van Wijk XMR, Ratain MJ, O'Donnell PH. Pharmacogenomic-Based Decision Support to Predict Adherence to Medications. Clin Pharmacol Ther 2020;108:368-76. [PMID: 32236960 DOI: 10.1002/cpt.1838] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
9 Schmidlen T, Sturm AC, Scheinfeldt LB. Pharmacogenomic (PGx) Counseling: Exploring Participant Questions about PGx Test Results. J Pers Med 2020;10:E29. [PMID: 32340147 DOI: 10.3390/jpm10020029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Johnson D, Hughes D, Pirmohamed M, Jorgensen A. Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials. J Pers Med 2019;9:E42. [PMID: 31480618 DOI: 10.3390/jpm9030042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Brunham LR, Baker S, Mammen A, Mancini GBJ, Rosenson RS. Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. Cardiovasc Res 2018;114:1073-81. [PMID: 29878063 DOI: 10.1093/cvr/cvy119] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
12 Stein R, Ferrari F, Scolari F. Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights. Curr Cardiol Rep 2019;21:68. [PMID: 31227920 DOI: 10.1007/s11886-019-1161-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 6.7] [Reference Citation Analysis]
13 Borden BA, Lee SM, Danahey K, Galecki P, Patrick-Miller L, Siegler M, Sorrentino MJ, Sacro Y, Davis AM, Rubin DT, Lipstreuer K, Polonsky TS, Nanda R, Harper WR, Koyner JL, Burnet DL, Stadler WM, Kavitt RT, Meltzer DO, Ratain MJ, O'Donnell PH. Patient-provider communications about pharmacogenomic results increase patient recall of medication changes. Pharmacogenomics J 2019;19:528-37. [PMID: 30713337 DOI: 10.1038/s41397-019-0076-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
14 Vassy JL, Chun S, Advani S, Ludin SA, Smith JG, Alligood EC. Impact of SLCO1B1 Pharmacogenetic Testing on Patient and Healthcare Outcomes: A Systematic Review. Clin Pharmacol Ther 2019;106:360-73. [PMID: 30137643 DOI: 10.1002/cpt.1223] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
15 Peyser B, Perry EP, Singh K, Gill RD, Mehan MR, Haga SB, Musty MD, Milazzo NA, Savard D, Li Y, Trujilio G, Voora D. Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings. Circ Genom Precis Med 2018;11. [DOI: 10.1161/circgen.118.002228] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
16 Jacobson TA, Edelman SV, Galipeau N, Shields AL, Mallya UG, Koren A, Davidson MH. Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©. Patient 2017;10:321-34. [PMID: 27981439 DOI: 10.1007/s40271-016-0211-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
17 Rumyantsev NA, Kukes VG, Kazakov RE, Rumyantsev AA, Sychev DA. [Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy]. Ter Arkh 2017;89:82-7. [PMID: 28252633 DOI: 10.17116/terarkh201789182-87] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Jörntén-Karlsson M, Pintat S, Molloy-Bland M, Berg S, Ahlqvist M. Patient-Centered Interventions to Improve Adherence to Statins: A Narrative Synthesis of Systematically Identified Studies. Drugs 2016;76:1447-65. [PMID: 27677773 DOI: 10.1007/s40265-016-0640-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
19 Friede K, Li J, Voora D. Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease. Clinical Chemistry 2017;63:177-85. [DOI: 10.1373/clinchem.2016.255232] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
20 Singh K, Peyser B, Trujillo G, Milazzo N, Savard D, Haga SB, Musty M, Voora D. Rationale and design of the SLCO1B1 genotype guided statin therapy trial. Pharmacogenomics 2016;17:1873-80. [PMID: 27807988 DOI: 10.2217/pgs-2016-0065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
21 Kitzmiller JP, Mikulik EB, Dauki AM, Murkherjee C, Luzum JA. Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016;9:97-106. [PMID: 27757045 DOI: 10.2147/pgpm.s86013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
22 Chambliss AB, Chan DW. Precision medicine: from pharmacogenomics to pharmacoproteomics. Clin Proteomics 2016;13:25. [PMID: 27708556 DOI: 10.1186/s12014-016-9127-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
23 Haga SB, Mills R, Moaddeb J, Allen Lapointe N, Cho A, Ginsburg GS. Patient experiences with pharmacogenetic testing in a primary care setting. Pharmacogenomics 2016;17:1629-36. [PMID: 27648637 DOI: 10.2217/pgs-2016-0077] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
24 Mikhailidis DP, Katsiki N, Athyros VG. Adherence to statin treatment: an important issue in clinical practice. Curr Med Res Opin 2016;32:1639-40. [PMID: 27357858 DOI: 10.1080/03007995.2016.1207621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]